PDRN
CAS 9007-47-4
Purity≥95.0%
Polynucleotide material for topical cosmetic formulation research
For B2B ingredient sourcing, request the specification, batch COA, sample, packaging and lead-time confirmation. Explore personal-care ingredients.
Confirm source, molecular-size profile and nuclease controls.
Key Specifications
| Product Positioning | Polynucleotide material for topical cosmetic formulation research |
| Application Scenarios | topical gel prototypes · polynucleotide formulation research · molecular-size characterization |
| CAS Number | 9007-47-4 |
| Purity | ≥95.0% |
| Molecular Formula | Polymer |
| Molecular Weight | 50–1500 kDa |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water |
| Storage | 2–8°C, protect from light |
| Shelf Life | 24 months |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
Polydeoxyribonucleotide (PDRN, CAS 9007-47-4) is a biopolymer composed of chains of deoxyribonucleotides — short-to-medium fragments of double-stranded DNA — with a broad molecular weight distribution typically spanning 50-1500 kDa. DNA of this type occurs naturally in the cell nuclei of all living organisms; commercial bulk PDRN is conventionally produced from the milt (sperm) of salmon or trout, a fish-processing byproduct whose DNA sequence and base composition are highly homologous to human DNA, supporting good biocompatibility. At industrial scale, the raw genetic material is extracted, purified to remove proteins and other cellular residues, and controllably depolymerized to the target fragment-length range, then sterile-filtered and lyophilized into a stable white powder suitable for cosmetic and pharmaceutical-grade formulations.
High Assayed Purity
Each batch is assayed at ≥95.0% purity by HPLC, meeting the specification threshold required for cosmetic-grade and pharmaceutical-intermediate applications.
Controlled Depolymerization Process
A tightly monitored enzymatic/controlled depolymerization step keeps the DNA fragment population within the 50-1500 kDa target window, supporting batch-to-batch molecular weight consistency.
Stable Lyophilized Form
Supplied as a white lyophilized powder that is fully water-soluble, offering good handling stability and a long shelf life under recommended storage conditions.
Full Contaminant Screening
Every lot is screened for heavy metals (Pb, Hg, Cd, As) and microbial limits (total plate count, yeast & mold, E. coli, Salmonella) to support downstream regulatory documentation.
Flexible Bulk & OEM Supply
Available in flexible bulk packaging with OEM/private-label and custom concentration or blend support for cosmetic formulators and finished-product brands.
Test items, specifications and batch results are shown here; request the formal COA through the card below.
Batch No.
PGPDRN-260408
Test date
2026-04-10
Specification
In-house
Pack size
1kg/bag
Storage
2–8°C, protect from light
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White lyophilized powder | Conforms |
| Odor | Odorless or faint characteristic odor | Conforms |
| Solubility | Soluble in water | Conforms |
| Assay (Purity, HPLC) | ≥95.0% | 96.5% |
| Molecular Weight (Mw) | 50-1500 kDa | Within range (~600 kDa avg.) |
| Loss on Drying | ≤8.0% | 4.8% |
| pH (1% aqueous solution) | 6.0-8.0 | 7.1 |
| Lead (Pb) | ≤2 mg/kg | <1 mg/kg |
| Mercury (Hg) | ≤1 mg/kg | <0.1 mg/kg |
| Cadmium (Cd) | ≤1 mg/kg | <0.1 mg/kg |
| Arsenic (As) | ≤2 mg/kg | <1 mg/kg |
| Total Plate Count | ≤1000 CFU/g | <100 CFU/g |
| Yeast & Mold | ≤100 CFU/g | <10 CFU/g |
| Pathogens (E. coli / Salmonella) | Negative/25g | Negative |
This page shows a batch-data summary only. No direct COA file link is provided; request the signed document through the form below.
Injectable formulations
Sterile vials and prefilled syringes
Serums and ampoules
Creams and eye creams
Facial masks
Clinical PDRN evidence is concentrated in sterile injectable protocols for wound and scar care. Development must define molecular-weight distribution, source, purity, endotoxin, sterility, container closure and professional-use instructions.
Evidence: Medical-use development requires jurisdiction-specific drug or device authorization and cannot be inferred from cosmetic-grade material.Source
Commercial PDRN serums, ampoules and creams commonly pair PDRN with hyaluronic acid, glycerin, niacinamide or ceramides. Development should prioritize delivery, preservation and polymer compatibility rather than assuming injectable evidence transfers to intact skin.
Evidence: Market-form and formulation rationale; cosmetic finished-product testing is required for efficacy claims.Source
Literature-Supported Research Directions
A randomized double-blind placebo-controlled trial enrolled 216 people with hard-to-heal diabetic foot ulcers. Intramuscular and perilesional PDRN increased complete healing and shortened median healing time. This was a medical injectable protocol and cannot support claims for cosmetic raw material or self-use.
Citation: Squadrito et al., Journal of Clinical Endocrinology & Metabolism 99 (2014), E746–E753. PMID: 24483158.View source
In a randomized controlled trial of 44 patients, two early postoperative PDRN injections reduced vascularity, erythema, scar height and subjective symptoms at three months, although the total scar-score difference narrowly missed conventional significance. The evidence is procedure- and injection-specific.
Citation: Kim et al., Advances in Wound Care 12 (2023), 361–370. PMID: 35713247.View source
A recent study tested 0.1% medium-length PDRN eye cream in laboratory, reconstructed-skin and 28-day split-face clinical models, reporting signaling and cosmetic changes. Results are formulation-specific, short term and require independent replication before broad raw-material claims.
Citation: Topical medium-length PDRN study, 2026. PMID: 42430369.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
10 g
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Insulated Box + Carton
For products requiring temperature-controlled transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Raw Material Sourcing & Pretreatment
Milt (sperm) tissue from salmon or trout, a fishery processing byproduct, is collected, cleaned, and homogenized as the starting biological raw material.
Cell Lysis & DNA Extraction
Cells are lysed and native high-molecular-weight DNA is released and separated from proteins, lipids, and other cellular debris.
Deproteinization & Primary Purification
Repeated deproteinization, precipitation, and filtration steps remove residual protein and RNA to obtain a purified DNA intermediate.
Enzymatic/Controlled Depolymerization
The purified DNA is subjected to a controlled enzymatic or physical depolymerization step that fragments the polymer to the target 50-1500 kDa molecular weight distribution.
Chromatographic Purification & Endotoxin Removal
Chromatography and further precipitation cycles refine the fragment profile and reduce endotoxin and trace protein/RNA to specification.
Sterile Filtration & Concentration
The purified solution is sterile-filtered and concentrated in preparation for drying.
Freeze-Drying (Lyophilization)
The concentrate is freeze-dried under controlled vacuum conditions to yield a stable white lyophilized powder.
QC Testing, Milling & Release
Finished powder is milled/homogenized for uniformity, then tested for purity, molecular weight distribution, heavy metals, and microbial limits before batch release.
Purity is determined by reverse-phase or ion-exchange HPLC referenced against a characterized PDRN standard, typically supported by UV absorbance (A260) ratios and SEC/GPC-based molecular weight distribution analysis. Buyers should request the batch Certificate of Analysis and confirm the exact assay method, the reported molecular weight range, and residual protein/RNA and endotoxin levels against their own formulation or regulatory requirements before large-volume procurement.
Marketed PDRN/PN products include regulated injectable presentations and cosmetic serums, ampoules, creams, eye creams and masks. Injectable development requires sterile-drug controls and jurisdiction-specific authorization. Topical products require molecular-size, delivery, preservation and finished-product efficacy validation.
Purity is confirmed by HPLC against a reference standard, with each batch accompanied by a Certificate of Analysis. Buyers may also request supplementary UV or SEC/GPC molecular weight data for independent confirmation.
Our PDRN is produced from salmon/trout milt DNA through extraction, deproteinization, controlled enzymatic depolymerization to the target 50-1500 kDa range, chromatographic purification, sterile filtration, and lyophilization.
Yes, PDRN is soluble in water. We recommend controlled reconstitution and cold storage of prepared solutions, as fragment integrity can be sensitive to pH, ionic strength, and temperature.
Yes, small trial samples are available for formulation evaluation and in-house testing prior to bulk commitment. Please contact our sales team with your intended application for sample arrangement.
Third-party test reports (e.g., purity, heavy metals, microbial limits) can be arranged for qualifying order volumes upon request; please discuss testing scope and turnaround with our sales team.
Yes, we support OEM/private-label supply, including custom concentration, blending with complementary actives, and customized documentation to fit your brand requirements.
Standard bulk packaging (e.g., foil bags or drums with double-layer moisture protection) is available, with flexible packaging sizes and formats to accommodate different order volumes.
MOQ varies by packaging format and intended use; please contact our sales team with your target volume, application, and destination country to receive a tailored quotation.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Issued with each shipment
Technical Resources
A formulation-focused guide to screen PDRN, GHK-Cu, and ceramide ingredients for serums, creams, masks, and other personal-care formats without turning preliminary science into finished-product claims.
PDRN sourcing conversations tend to focus on purity and origin. The number that actually determines whether a lot fits your application is one that gets less attention: molecular weight distribution.
Related Products
GHK-Cu Powder (Copper Tripeptide-1)
Interested in PDRN?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
